Biotechnology Archives - Page 2 of 10

Friday Jul 09, 2021 - 9:44 am

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in William Blair Biotech Focus Conference

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be part of this year’s online William Blair Biotech Focus Conference. VTGN management will participate in a panel discussion titled “Updates in Neuropsych.” Key executives will…

Thursday Jul 08, 2021 - 11:05 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Brings Cutting-Edge Tech to the Neurology Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed cutting-edge tech that bridges the widening gap in access to quality care. The company’s clinical-grade neurological devices, NeuroCap(TM) and NeuroEEG(TM), are portable, cost-efficient, easy-to-use, and allow for long-term monitoring. This technology will be part of a ketamine clinical study conducted by Ehave Inc. (OTC: EHVVF) to establish the statistical…

Wednesday Jul 07, 2021 - 1:22 pm

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome

Vivos Therapeutics (NASDAQ: VVOS) has released data from an independent patient survey related to its proprietary Vivos treatment for dental tissue anomalies and dentofacial malformations associated with obstructive sleep apnea (“OSA”) and other debilitating health conditions. The study reported that approximately 97% of patients surveyed said that they had achieved their desired outcome from the Vivos treatment for their OSA. Other study results show that…

Wednesday Jul 07, 2021 - 12:15 pm

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Key Board Appointment of Mary L. Rotunno

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Mary L. Rotunno, J.D. to its board of directors. “Mary brings to our team more than 30 years of leadership experience, which began with serving patients as a registered…

Wednesday Jul 07, 2021 - 9:50 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Collaboration with the University of Michigan

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced an agreement with the University of Michigan to perform research related to Tryp's Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. According to the update, the collaboration is part of a series of upcoming bridging studies designed to expand Tryp's intellectual property portfolio…

Friday Jul 02, 2021 - 10:39 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result…

Friday Jul 02, 2021 - 10:24 am

InvestorNewsBreaks – Brain Scientific Inc.’s (BRSF) Pediatric NeuroCap Is First-of-its-Kind for Pediatric Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is bringing to market new technology that allows EEG testing to be deployed rapidly and accurately in children and adolescents. The Pediatric NeuroCap is intended to solve significant barriers limiting EEG monitoring in pediatric care. “Instead of improvising to make adult-size EEG electrodes fit pediatric patients’ smaller head circumference, Brain Scientific…

Thursday Jul 01, 2021 - 2:35 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Finalizing Design of Innovative Cancer Visualization Technology

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design of its i/Blue Imaging System(TM), with manufacturing expected to be completed in 2022. The system is an innovative technology designed to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. It solves challenges associated with using blue and white light cystoscopies, which require surgeons to switch back and forth…

Thursday Jul 01, 2021 - 12:37 pm

InvestorNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Strides in Treatment Innovation Highlighted in New Book

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA”). Years of research have culminated in its main product, the Vivos System, which has been instrumental in treating OSA among adults. In his new book, Pneumopedics and Craniofacial Epigenetics, Vivos Therapeutic’s…

Thursday Jul 01, 2021 - 12:21 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Advance Psychedelic Medicine Program

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is partnering with pharmaceutical research companies that will provide support services for the development of its synthetic TRP-8802 psilocybin product. This is on top of a collaboration with pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida, who is directing the investigation/clinical trials of the product. Fluence, a psychedelic therapy educational platform, will provide design and…

Wednesday Jun 30, 2021 - 10:02 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Finalizes Supply Agreement with Two German Companies for COVID-19 PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has inked a master supply agreement with two German diagnostics, testing, and medical logistics companies: Beovita GmbH & Co. KG and Tackleberries GmbH. The two companies run 10 COVID-19 test centers in Berlin. The supply agreement outlines the delivery of approximately 1,000 of XPhyto’s proprietary Covid-ID Lab…

Tuesday Jun 29, 2021 - 10:47 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives FDA Fast Track Status for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the U.S. Food and Drug Administration granted Fast Track Designation for Berubicin, the company’s lead investigational drug. The status was received for the company’s evaluation of Berubicin for the treatment of patients with recurrent glioblastoma multiforme (“GBM”).…

Friday Jun 25, 2021 - 10:44 am

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Conference Call to Discuss 2021 FY Results, Provide Business Update

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will host a conference call to provide a business update and discuss financial and operating results for its fiscal year ended March 31, 2021. The call is scheduled to begin…

Thursday Jun 24, 2021 - 9:59 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Take Virtual Stage at Psych Investor Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs, today announced that it is presenting at the Psych Investor Summit: Research & Development. The conference is slated to take place virtually on July 7. Tryp’s chairman and CEO Greg McKee will present information on the company and its drug development pipeline, with his presentation scheduled…

Wednesday Jun 23, 2021 - 2:57 pm

InvestorNewsBreaks – Healthy Extracts Inc. (HYEX) Focused on Greater Supplement Effectiveness

Healthy Extracts (OTCQB: HYEX) develops, sells and distributes proprietary products with proven health benefits through its portfolio of wholly owned subsidiaries that currently comprises Ultimate Brain Nutrients(TM) (“UBN”) and BergametNA(TM). UBN creates formulations that improve brain health while BergametNA develops powerfully proven supplements sourced from the Citrus Bergamot Superfruit(TM) (“bergamot”) and which target cardiovascular and immune health. “Bergamot has a host of health benefits as…

Wednesday Jun 23, 2021 - 2:26 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate in Access to Giving Virtual Investor Conference

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, will participate in the Access to Giving investor conference. The conference, scheduled for July 13–15, 2021, is the first of its kind focused on investor education and advocacy. More than 50 companies will be involved in the event, with presentations…

Wednesday Jun 23, 2021 - 2:15 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Setting Stage for Strengthened Demand for Blue Light Cystoscopy

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is working closely with manufacturing partner Lighthouse Imaging on its proprietary i/Blue Imaging System(TM) and is on target to conduct private demonstrations at the annual American Urology Association meeting set for early September. “The updated product design will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems and feedback from preliminary meetings with…

Wednesday Jun 23, 2021 - 10:46 am

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) to Present, Share Highlights at Emerging Growth Conference

Pressure BioSciences (OTCQB: PBIO) has announced its CEO will be participating in the upcoming Emerging Growth Conference. PBIO is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the worldwide life sciences, agriculture, food & beverage, and other key industries. Slated for June 23, the real-time, interactive investor conference has scheduled 10 companies to present for 30-45…

Tuesday Jun 22, 2021 - 1:40 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Novel Treatments Forward with Key Focus on Berubicin

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead drug candidate, Berubicin, is a novel anthracycline, the first of which to appear capable of crossing the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin in the treatment of several serious brain and central nervous system oncological indications. CNS is set to commence patient enrollment in a potentially pivotal study to evaluate the efficacy of…

Tuesday Jun 22, 2021 - 1:19 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Advancing Rotigotine Development Program for Parkinson’s

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A recent article reads, “A Q1 trial announced in January 2021 and focusing on a human bioavailability pilot study of the Rotigotine transdermal patch for…

Monday Jun 21, 2021 - 1:42 pm

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Partnering to Improve Standard of Care, Provide Turnkey Solutions in Plant-Based Medicine

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is working with doctors as well as government and university research centers to reduce the variations in treatment plans and trials. The company, which has developed and uses dose-measuring internet-of-things (“IoT”) devices to collect HIPPA-compliant data to improve future medical treatments, is guided by the need to transform patient care. Key to…

Monday Jun 21, 2021 - 11:28 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Revolutionizing Portable EEG Diagnostics Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company, has created powerful yet affordable solutions that bring brain diagnostics to settings where it was previously impossible or difficult to conduct neurological testing. Concussions resulting from head trauma in contact sports are usually minor; however, some can lead to significant long-term cognitive, physical and psychosocial impairments. “Unfortunately,” observes a recent article, “at this moment,…

Friday Jun 18, 2021 - 1:32 pm

InvestorNewsBreaks – United Medical Equipment Business Solutions Network Inc. Differentiating Itself as Premier Provider of Vital Products

United Medical Equipment (“UME,” “UMEBSNI”) stands out in an environment fraught with fraudsters who emerged due to the soaring demand for personal protective equipment (“PPE”). “As the virus spread, an immediate and drastic need for personal protective equipment exploded. This soaring demand for PPE was quickly accompanied by PPE-related fraud,” notes a recent article. PPE fraud involves selling counterfeit testing kits, surgical gowns, gloves, facial…

Thursday Jun 17, 2021 - 2:33 pm

InvestorNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Innovative System Expected to Lead to More Successful Surgical Outcomes

Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed and patented its i/Blue Imaging System(TM), which will directly address the problems associated with treating early stage bladder cancer using existing cystoscope technology. “Current technology shows only one image at a time, requiring the surgeon to constantly switch back and forth between the white and blue light images. The switching process makes orientation and navigation within the…

Thursday Jun 17, 2021 - 10:02 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Featured Guest in Latest Stock2Me Podcast

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced that chairman and CEO Greg McKee was interviewed on the most recent episode of the Stock2Me Podcast. The podcast features a fascinating array of companies and individuals that are actively revolutionizing business practices within their respective markets. In the interview, McKee talked about the…

Wednesday Jun 16, 2021 - 10:43 am

InvestorNewsBreaks — Brain Scientific Inc. (BRSF) Announces Acquisition Agreement

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has entered into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric motion technology. According to the announcement, the merger is designed to expand the market reach of both companies along with their ability to deliver innovative technologies to high-growth markets. Both companies have built impressive teams of scientists, engineers and…

Tuesday Jun 15, 2021 - 2:00 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Create Safer, More Effective Protocol in ‘Fast-Moving Arena of Psychedelic Therapies’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is collaborating with psychedelic therapy educational platform Fluence to provide design and training for the psychotherapeutic portion of its Phase 2a clinical trials for treating eating disorders and fibromyalgia. “Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic…

Friday Jun 11, 2021 - 11:22 am

InvestorNewsBreaks – Brain Scientific Inc.’s (BRSF) Disposable Technology Vital Amid Ongoing Pandemic

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed sanitary, disposable EEG caps that are proving useful amid the ongoing pandemic. “When fighting a highly contagious disease, disposable technology is vital,” notes a recent article. This is where NeuroCap(TM) and NeuroEEG(TM), the company’s two FDA-cleared devices, can help. They offer cost-efficient, portable neurological monitoring.” The article observes that…

Thursday Jun 10, 2021 - 12:52 pm

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Subsidiary Publishes Data Report on Medical Cannabis Use for Pain Management

RYAH Group (CSE: RYAH) today announced that its wholly owned subsidiary, RYAH Medtech Inc., has published a data report on the use of medical cannabis among patients with pain conditions. According to the update, the report features insights into the use of cannabis to treat pain conditions by patients within the RYAH Data ecosystem and whether cannabis may be one of the alternative treatment solutions…

Thursday Jun 10, 2021 - 12:43 pm

InvestorNewsBreaks – Healthy Extracts Inc.’s (HYEX) HERHEART(TM) Packs a ‘Whole Host of Health Benefits’

Healthy Extracts (OTCQB: HYEX), through its wholly owned subsidiary BergaMet NA(TM), has developed HERHEART(TM), an exclusive supplement scientifically formulated specifically for women to improve perimenopausal symptoms and cardiovascular health. The supplement’s development was influenced by the statistic that cardiovascular disease is the leading cause of death in women globally. A recent article notes, “A 2020 clinical study revealed that HERHEART reduced mood swings and hot…

Thursday Jun 10, 2021 - 12:36 pm

InvestorNewsBreaks – United Medical Equipment Business Solutions Network Inc. Expands Medication Management App with GoodRX

United Medical Equipment (“UME,” “UMEBSNI”) helps families with resources and provides a network of reliable solutions such as the Medication Management App. Available on both iOS and Android, the app is designed to provide direct and indirect patient care and education for care professionals, caregivers, students, and family members. “GoodRX is the newest addition to the app’s functions,” reads a recent article. “This feature allows…

Wednesday Jun 09, 2021 - 12:22 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Aims for New Standard of Care in Visualizing Cancer

Imagin Medical’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) is designed to enhance tumor visualization and resection, potentially lowering recurrence rates. With a focus on establishing a new standard of care in the visualization of cancer during minimally invasive procedures, Imagin Medical is initially targeting bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common in men. Imagin’s i/Blue Imaging…

Tuesday Jun 08, 2021 - 11:41 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) Announces Participation at Ladenburg Thalmann Healthcare Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be presenting at the upcoming Ladenburg Thalmann Healthcare Conference. The all-virtual conference is scheduled for July 13–14, 2021. Tryp chair and CEO Greg McKee, president and chief science officer Jim Gilligan and CFO Luke Hayes will participate in the…

Tuesday Jun 08, 2021 - 10:07 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update on Timely Progression of Psychedelic Medicine Program

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that its GMP mescaline synthesis program is on schedule with the completion of initial production batches. According to the update, the industrial-scale manufacture of pharmaceutical-grade psychedelic compounds, including mescaline and psilocybin, is an important part of XPhyto's psychedelic medicine program and will provide a foundation for its drug formulation and clinical validation work. “With both…

Friday Jun 04, 2021 - 10:35 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Filling EEG Testing Gap in Pediatric Brain Diagnostics

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, was the subject of a feature piece published by Med-Tech News, a publication covering medical devices and manufacturing. The article, authored by the marketing director of BRSF, Irina Nazarova, noted that the need for EEG devices within the pediatric segment often went unmet, even though children can suffer from a number…

Wednesday Jun 02, 2021 - 1:39 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Nears Dosing of Phase 2 Patients with Standout Anthracycline Therapy

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on producing a treatment that improves on the effectiveness of established chemotherapy drug lomustine in increasing overall survival rates of glioblastoma multiforme (“GBM”) patients. GBM is an illness that is nearly 100% fatal in patients just over a year after diagnosis. CNS Pharmaceuticals’ lead drug candidate, Berubicin, has been granted investigational new drug (“IND”) status after promising findings. “Berubicin…

Wednesday Jun 02, 2021 - 1:30 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building Strong Commercial Pipeline for Unique PeDAL(TM) Platform

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease. “We are building a strong commercial pipeline for our unique Patient-cEntric…

Tuesday Jun 01, 2021 - 12:39 pm

InvestorNewsBreaks – InvestorBrandNetwork, BioMedWire to Collaborate with Q1 Productions for Slate of Upcoming Events

InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, today announced that it will collaborate with Q1 Productions as an official media sponsor for its full event lineup in 2021. IBN also announced that BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands part of the InvestorBrandNetwork, will also be joining as an official media sponsor for…

Tuesday Jun 01, 2021 - 11:28 am

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Completes Initial Shipment for Major Plant-Based Medicine Trial

RYAH Group (CSE: RYAH) today announced that it has completed the first shipment of the RYAH Smart Dry Herb Inhalers, which includes a delivery of approximately 10,000 RYAH Cartridges and QR Codes to an international clinic undertaking one of the world’s largest and most comprehensive clinical trials in plant-based medicine. The initial shipment is designated to be used by the clinic in a pilot run…

Friday May 28, 2021 - 12:34 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Potential Expansion of ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently received the CE-IVD approval (European certification) of its 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”). The approval facilitated initial sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East and North America. The company also recently announced delivery of 2,000 units of Covid-ID Lab…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions